Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.

McGregor CG., Adams A., Sadler R., Arancibia-Cárcamo CV., Palmer R., Ambrose T., Brain O., Walsh A., Klenerman P., Travis SP., Croft NM., Lindsay JO., Satsangi J.

DOI

10.1136/gutjnl-2021-324116

Type

Journal article

Publication Date

2021-12-01T00:00:00+00:00

Volume

70

Pages

2398 - 2400

Total pages

2

Keywords

COVID-19, inflammatory bowel disease, infliximab, paediatric gastroenterology, Antibodies, Monoclonal, Humanized, COVID-19, Humans, Inflammatory Bowel Diseases, Infliximab, Pandemics, SARS-CoV-2, United Kingdom

Permalink More information Close